Torre and his team faced off against a team led by John Legend and Chrissy Teigen. Torre was tasked with anchoring the Fast Money segment and he did not disappoint. Full video of Pablo Torre ...

Learn More Aleph Alpha, a German artificial intelligence startup, released two new large language models (LLMs) under an open license on Monday, potentially reshaping the landscape of AI development.

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early breast cancer. The FDA has greenlighted Novartis’ Kisqali, used in ...

No, there’s only one man that deserves that honor for 2024. And it’s ESPN and Meadowlark Media star Pablo Torre thanks to his heroics on Celebrity Family Feud. Torre and fellow ESPN ...

Milan Jaros / Bloomberg via Getty Images Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along ...

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...

Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs. For $20 million ...

Aleph Zero will work alongside the world’s largest telecommunications organizations to help to develop standardized blockchain APIs for the industry Aleph Zero, a blockchain ecosystem engineered ...

Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that will be closely compared with a rival product from Eli Lilly. Novartis ...

"Blockchain technology is rapidly expanding into diverse industries, powering an ever-growing array of use cases," said Antoni Zolciak, Co-founder of Aleph Zero. "As this landscape evolves ...

Novartis has partnered with Versant Ventures to establish Borealis Biosciences, a Canada-based independent, discovery-stage biotech company. The collaboration has resulted in $150m Series A ...